Dec 23 |
Bemnifosbuvir for COVID-19: real-time meta analysis of 3 studies | |
| Significantly lower risk is seen for hospitalization. 2 studies from 2 independent teams in 2 countries show significant benefit. Meta analysis using the most serious outcome reported shows 47% [-57‑82%] lower risk, without rea.. | ||
Jan 8 |
et al., Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkae122 (date from preprint) | Human bronchopulmonary disposition and plasma pharmacokinetics of oral bemnifosbuvir (AT-527), an experimental guanosine nucleotide prodrug for COVID-19 |
| Phase 1 study showing effective lung delivery and safety of the oral COVID-19 antiviral candidate bemnifosbuvir (AT-527) at 550mg twice daily. Authors found AT-527 550mg BID achieved sustained antiviral drug levels in lung fluids that exc.. | ||
Nov 1 2023 |
et al., Future Virology, doi:10.2217/fvl-2023-0115 | Oral bemnifosbuvir (AT-527) vs placebo in patients with mild-to-moderate COVID-19 in an outpatient setting (MORNINGSKY) |
| 71% lower hospitalization (p=0.05), 28% lower progression (p=0.49), 28% slower recovery, and 22% improved viral clearance (p=0.21). MORNINGSKY RCT which was terminated early after enrolling only 216 of 1,386 planned participants. The trial did not meet its primary endpoint, with the bemnifosbuvir group having longer time to symptom improvement than placebo. However, c.. | ||
Aug 17 2023 |
et al., Microbiology Spectrum, doi:10.1128/spectrum.00077-23 | A Phase 2 Randomized Trial Evaluating the Antiviral Activity and Safety of the Direct-Acting Antiviral Bemnifosbuvir in Ambulatory Patients with Mild or Moderate COVID-19 (MOONSONG Study) |
| 3% improved viral clearance (p=0.14). RCT 100 mild/moderate COVID-19 patients showing no significant difference in nasopharyngeal viral load reduction between bemnifosbuvir (550mg or 1100mg twice daily for 5 days) and placebo groups. | ||
Jun 23 2023 |
et al., Future Virology, doi:10.2217/fvl-2023-0064 | Phase II study of bemnifosbuvir in high-risk participants in a hospital setting with moderate COVID-19 |
| 86% lower mortality (p=0.24), 2% improved recovery (p=1), and 9% improved viral clearance (p=0.8). Phase 2 RCT investigating bemnifosbuvir for the treatment of 81 high-risk COVID-19 patients hospitalized with moderate disease. The trial was terminated early due to difficulties with enrollment. There was no significant difference betwee.. | ||
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.